Advanced Filters
noise

Dallas, Texas Clinical Trials

A listing of Dallas, Texas clinical trials actively recruiting patient volunteers.

Found 762 clinical trials
B Bruck Habtemariam

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

12 - 95 years of age All Phase 1/2
J Julia A Hiner, MD

DETECT-RPC Universal EM Screening

The purpose of this study is to evaluate whether the use of the Detection of Elder Mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool increases the average reporting of elder mistreatment (EM) by homebased primary care (HBPC) clinicians.

18 years of age All Phase N/A
K Keith Baker

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending …

18 years of age All Phase 1/2
D Denise Morgott

NE3107 in Adults With Neurological Symptoms of Long COVID

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to …

18 - 64 years of age All Phase 2

Targeted Plasticity Therapy for PTSD

Objectives of this study are to provide continued safety assessment for the ReStore system, and to gain further estimates of the effect size of Vagus Nerve Stimulation (VNS) therapy with Prolonged Exposure Therapy (PE) compared to PE with placebo (sham) stimulation in participants with posttraumatic stress disorder (PTSD)

22 - 79 years of age All Phase N/A

Empowering Perinatal Adolescents Through Writing

This is a feasibility and acceptability study of Written Exposure Therapy (WET) for PTSD in pregnant and postpartum adolescents and youth with PTSD.

15 - 24 years of age Female Phase N/A
A Ashley Scherer

A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM

Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.

22 years of age All Phase N/A
E Erin Venza

Exploring Neurophysiological Markers of Brain Health

The combination of transcranial magnetic stimulation (TMS) and electroencephalography (EEG) has been suggested as a promising brain imaging tool for identifying biomarkers of brain health. In this pilot study, study investigators will explore the neurophysiological metrics of brain health with a non-invasive brain imaging technique, alongside behavioral and fMRI metrics …

22 - 100 years of age All Phase N/A

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

13 years of age All Phase 3

The Role of Sirolimus in Preventing Functional Decline in Older Adults

Aging is associated with progressive impairment of tissue and organ function, resulting in increased susceptibility to chronic disease, frailty and disability. Currently there are limited treatment options to alter this inevitable process. The proposed work has the potential to identify a new therapeutic intervention to decrease aging-related degenerative processes. Rapamycin …

65 - 80 years of age All Phase 2

Simplify language using AI